Get the Stockscreener App
0.4788
12.63%
-0.0692
Onconetix Inc stock is traded at $0.4788, with a volume of 583.33K.
It is down -12.63% in the last 24 hours and down -27.83% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
See More
Previous Close:
$0.548
Open:
$0.5218
24h Volume:
583.33K
Relative Volume:
0.11
Market Cap:
$2.51M
Revenue:
$735.20K
Net Income/Loss:
$-9.70M
P/E Ratio:
-0.0011
EPS:
-435.729
Net Cash Flow:
$-9.80M
1W Performance:
-22.77%
1M Performance:
-27.83%
6M Performance:
-93.70%
1Y Performance:
-99.72%
1-Day Range:
$0.4625
$0.5299
1-Week Range:
$0.4625
$0.6007
52-Week Range:
$0.4625
$200.00
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.4788 | 2.51M | 735.20K | -9.70M | -9.80M | -435.73 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Onconetix Inc Stock (ONCO) Latest News
Onconetix, Inc. (ONCO) — share price and filings - Howl.link
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Five proposals face a November 10 vote as Onconetix (ONCO) asks for another reverse split. - Stock Titan
Onconetix (NASDAQ: ONCO) must clear a cash hurdle to close its Realbotix takeover - Stock Titan
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition - Stock Titan
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition - The Manila Times
Onconetix Provides $2.5 Million Bridge Financing to Realbotix Ahead of Pending Acquisition - Quiver Quantitative
Onconetix Inc (NASDAQ: ONCO) Share Price, ONCO Stock News, ONCO Share Price & Updates - Kalkine
Could Onconetix (NASDAQ:ONCO) Face More Volatility on Nasdaq? - Kalkine Media
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Onconetix Inc Peer Comparison – Compare with Others - Value Research
Onconetix, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events - Yahoo Finance
Humanoid robot presenters get live trial as Onconetix (NASDAQ: ONCO) pursues Realbotix buyout - Stock Titan
Onconetix (NASDAQ: ONCO) flags going concern as 100M-share resale filed - Stock Titan
Onconetix, Inc. (ONCO) Stock Price & News - syfe.com
Onconetix Inc Key Financial Ratios – Valuation, Profitability & More - Value Research
Onconetix (ONCO) Reported Quarter: Available Data Shows the Latest Reported Performance for This Review; Shares Move 0.95% Lower in Latest TradingReturn On Assets - dars.gov.et
Onconetix (ONCO) Reported Quarter: Available Data Shows the Latest Reported Performance for This Review; Shares Move 0.95% Lower in Latest TradingGuidance Downgrade Alert - vinanet.vn
Onconetix (ONCO) Reported Quarter: Available Data Shows the Latest Reported Performance for This Review; Shares Move 0.95% Lower in Latest TradingDividend Earnings Report - dars.gov.et
Onconetix (ONCO) flags going concern risk as cash burn, impairments mount - Stock Titan
Onconetix, Inc. (ONCO) Debt 2025 - Stock Titan
Onconetix (NASDAQ: ONCO) resale filing covers 100M shares tied to PIPE - Stock Titan
Realbotix Q3 Results: Revenue Falls 40%, Loss Widens Amid Scaling - scanx.trade
Realbotix Plans Online-Only Robot Line With Buyer Deposits in 2026 - Stock Titan
Onconetix Inc (ONCO) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series - The Manila Times
Onconetix (ONCO) outlines Realbotix all-stock acquisition and humanoid robot TV role - Stock Titan
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series - GlobeNewswire
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series - Yahoo Finance
Onconetix subsidiary appoints co-founder to board - Investing.com
Onconetix subsidiary appoints co-founder to board By Investing.com - Investing.com Nigeria
Onconetix subsidiary appoints co-founder to board By Investing.com - Investing.com Canada
Onconetix subsidiary appoints co-founder to board By Investing.com - Investing.com South Africa
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - The Manila Times
Onconetix subsidiary appoints co-founder to board By Investing.com - Investing.com UK
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Caledonian Record
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - GlobeNewswire
ONCO Q1 2025 Earnings: Positive EPS of $0.25 Marks a Notable Bottom-Line QuarterBanking Earnings Report - vinanet.vn
Onconetix Inc (ONCO) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Onconetix Secures Major PIPE and Equity Facility Financing - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Onconetix (NASDAQ: ONCO) adds $750,000,000 ELOC and $30,249,600 PIPE - Stock Titan
Onconetix (ONCO) 13G: Keystone Capital reports 6.1% beneficial stake - Stock Titan
Onconetix Inc. (ONCO) Gains 3.46% as Shares Approach Resistance at $0.89Factor Timing - dars.gov.et
Onconetix Inc (ONCO) Balance Sheet - TradingKey
Onconetix Inc. (ONCO) Gains 3.46% as Shares Approach Resistance at $0.89Intraday Trade Ideas - vinanet.vn
Onconetix Inc (ONCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onconetix Inc (ONCO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Onconetix Inc (ONCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Onconetix Inc Stock (ONCO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Apr 20 '26 |
Sale |
0.75 |
94,462 |
70,846 |
83,359 |
| HRT FINANCIAL LP | 10% Owner |
Apr 17 '26 |
Buy |
0.73 |
34,636 |
25,284 |
177,821 |
| HRT FINANCIAL LP | 10% Owner |
Apr 16 '26 |
Sale |
0.73 |
53,867 |
39,323 |
143,185 |
| HRT FINANCIAL LP | 10% Owner |
Apr 15 '26 |
Buy |
0.76 |
92,554 |
70,341 |
197,052 |
| HRT FINANCIAL LP | 10% Owner |
Apr 14 '26 |
Buy |
0.77 |
74,350 |
57,250 |
104,498 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):